Global Monkeypox Virus Outbreak 2022: A Bibliometric Analysis

Abstract

Monkeypox is a rare zoonotic disease caused by the monkeypox virus, which spreads by direct contact mainly, thus having the propensity to cause future epidemics. The current review aimed to provide an up-todate literature analysis for evaluating scientific data on monkeypox. A bibliometric analysis was conducted through eight electronic databases. The search period was from May 2022 to December 2023. All the articles were exported to Mendeley (Elsevier, Amsterdam, Netherlands). The literature search resulted in 415 relevant research articles. The growth of publications gradually rose, initiated in January 2022, leading to a rapid upsurge in May 2022. A total of 409 documents reported the number of citations, with two articles documenting the highest number, ranging from 146-150 and 216-220. The European region (EURO) dominated in publishing research articles on monkeypox, with the United States having the highest number of reports (n = 41; 9.87%), followed by the United Kingdom (n = 35; 8.43%) and Italy (n = 15; 3.61%). There were 82 funding agencies that funded 44 research articles, whereas 371 were not funded by any funding agency. Our analysis has presented the outline of the research articles published on monkeypox virusrelated literature during the current outbreak. Research articles should be financially and administratively supported. Future research is required to expand research on the monkeypox virus, as there is a growing demand for original articles.

Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination

“…The study of the immunological markers of the response to OPXV in the human population has mainly focused on immunity to smallpox. Despite the increase in publications on MPXV infections and immunity observed in the last year [32], a limited number of reports focus on the response to the MPXV infection, and the level of cross-protection from MPXV due to vaccinia virus-based vaccines needs to be further investigated. We evaluated the presence of MPXV-binding and neutralizing antibodies and reactive T cells in a population of healthy donors with a history of smallpox vaccination.…”